This joint guidance from the PCDS and ABCD aims to support clinicians in selecting alternative glucose-lowering therapies when GLP-1 RAs are unavailable during this period of national shortage.
The Department for Health and Social Care (DHSC) have issued a National Patient Safety Alert regarding the shortage of glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
There are very limited, intermittent supplies of all GLP-1 RAs. Supplies are not expected to stabilise to meet full market demand until at least mid-2024. The supply issues have been caused by an increase in demand for these products for licensed and off-label indications.
MSN/2023/061
Tier 3 – high impact**
Date of issue: 27/06/2023
Link: Medicines Supply Tool
The Primary Care Diabetes Society (PCDS) and Association of British Clinical Diabetologists (ABCD) are very concerned about the ongoing national shortage affecting the availability of GLP-1 receptor analogues (GLP-1 RAs). This is very difficult for people with diabetes who are unable to access their GLP-1 RA medication, and for their clinicians who are unable to provide the treatment they feel is necessary.
Please find below, in the File(s) section of this page, the presentations featured at the DTN-UK Team Education Day 2023.
The 2023 Endocrinology & Diabetes Specialty Certificate Examination is proceeding as scheduled on 14th June 2023.
This two day conference will cover the core learning of previous EXTOD conferences, and will also offer an advanced second day to build on foundation knowledge.
Delegates can choose to book one or two days (please note that in order to book Day 2 (Advanced) you will have needed to have previously attended an EXTOD conference)
